2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

NCT00028821 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Refractory Multiple Myeloma
Stage III Multiple Myeloma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: 2-methoxyestradiol
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)